Bruck C, Thiriart C, Fabry L, Francotte M, Pala P, Van Opstal O, Culp J, Rosenberg M, De Wilde M, Heidt P, Heeney J
SmithKline Beecham Biologicals, Rixensart, Belgium.
Vaccine. 1994 Sep;12(12):1141-8. doi: 10.1016/0264-410x(94)90185-6.
In an attempt to compare the protective effect of vaccination with two forms of envelope antigens, and to define immunological correlates of protection against HIV infection, chimpanzees were vaccinated with either recombinant gp160 or gp120. Homologous HIV challenge was performed 3 weeks after the fourth immunization. The animal with the highest level of serum neutralizing antibodies (gp160 immunogen) was protected against HIV infection. All other chimpanzees became infected, but displayed various levels of infected PBMCs. The postchallenge data gave rise to the following conclusions: (1) protection correlated with the level of the serological immune response, but not with the nature of immunogen (gp120 versus gp160); (2) the virus-neutralizing titre at day of challenge correlated with protection from infection; (3) the relative magnitude of the lymphoproliferative T-cell response at day of challenge did not correlate with any protective effect; (4) the peak numbers of virus-infected PBMCs in vaccinated animals were lower than those observed in control animals, and this effect was correlated with the intensity of the antibody response at day of challenge. This raises the possibility that a beneficial effect of HIV vaccination may be achieved in a situation where sterile immunity is not consistently obtained.
为了比较两种包膜抗原形式的疫苗接种的保护效果，并确定针对HIV感染的保护的免疫相关因素，用重组gp160或gp120对黑猩猩进行了疫苗接种。在第四次免疫后3周进行同源HIV攻击。血清中和抗体水平最高的动物（gp160免疫原）受到了针对HIV感染的保护。所有其他黑猩猩都被感染，但显示出不同水平的感染外周血单核细胞。攻击后的数据分析得出以下结论：（1）保护与血清学免疫反应水平相关，但与免疫原的性质（gp120与gp160）无关；（2）攻击当天的病毒中和滴度与免受感染的保护相关；（3）攻击当天淋巴细胞增殖性T细胞反应的相对强度与任何保护作用均无关；（4）接种疫苗动物中病毒感染的外周血单核细胞的峰值数量低于对照动物中观察到的数量，并且这种效应与攻击当天抗体反应的强度相关。这增加了在不能始终获得无菌免疫的情况下可能实现HIV疫苗接种有益效果的可能性。
